Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 1.00 |
| ▸ | SYK | P43405 | 1/20 | 0.81 |
| ▸ | MEN1 | O00255 | 6/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.72 |
| ▸ | POLB | P06746 | 5/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.72 |
| ▸ | MAPT | P10636 | 4/20 | 0.72 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.72 |
| ▸ | RECQL | P46063 | 3/20 | 0.72 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.72 |
| ▸ | EIF4E | P06730 | 1/20 | 0.72 |
| ▸ | EIF4G1 | Q04637 | 1/20 | 0.72 |
| ▸ | THRB | P10828 | 1/20 | 0.72 |
| ▸ | MAP3K5 | Q99683 | 7/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4402019 | 1.00 | ENPP2 (1.00) | ENPP2SYKMEN1KMT2APOLB | |
| SCHEMBL1135868 | 0.90 | SYK (1.00) | ENPP2SYKMEN1KMT2APOLB | |
| SCHEMBL12668370 | 0.90 | SYK (1.00) | ENPP2SYKMEN1KMT2APOLB | |
| SCHEMBL30774050 | 0.90 | SYK (1.00) | ENPP2SYKMEN1KMT2APOLB | |
| SCHEMBL1135867 | 0.90 | SYK (1.00) | ENPP2SYKMEN1KMT2APOLB | |
| SCHEMBL3796210 | 0.89 | ENPP2 (0.80) | ENPP2SYKMEN1KMT2APOLB | |
| SCHEMBL29987110 | 0.89 | ENPP2 (0.80) | ENPP2SYKMEN1KMT2APOLB | |
| SCHEMBL3796207 | 0.89 | ENPP2 (0.80) | ENPP2SYKMEN1KMT2APOLB | |
| SCHEMBL8337281 | 0.88 | ENPP2 (0.78) | ENPP2SYKMEN1KMT2APOLB | |
| SCHEMBL3897831 | 0.87 | MAP3K5 (0.78) | ENPP2SYKMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1830848-B1 | USE OF THIAZOLIDINONE DERIVATIVES FOR THE TREATMENT OF SOLID TUMORS | CELL THERAPEUTICS EUROPE SRL (IT) | 2009-12-16 | — | — | EP | claimed |
| US-20080261980-A1 | Use of Thiazolidinone Derivatives as Antiangiogenic Agents | CELL THERAPEUTICS, INC. (US) | 2008-10-23 | — | — | US | claimed |
| WO-2020236668-A1 | LEUKADHERIN-1 ALONE OR IN COMBINATION FOR USE IN THE TREATMENT OF CANCER | GB006, INC. (US) | 2020-11-26 | — | — | WO | disclosed |
| EP-1830848-B1 | USE OF THIAZOLIDINONE DERIVATIVES FOR THE TREATMENT OF SOLID TUMORS | CELL THERAPEUTICS EUROPE SRL (IT) | 2009-12-16 | — | — | EP | disclosed |
| US-20080261980-A1 | Use of Thiazolidinone Derivatives as Antiangiogenic Agents | CELL THERAPEUTICS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| EP-1830848-A1 | USE OF THIAZOLIDINONE DERIVATIVES AS ANTIANGIOGENIC AGENTS | Cell Therapeutics Europe S.R.L. (IT) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006066846-A1 | USE OF THIAZOLIDINONE DERIVATIVES AS ANTIANGIOGENIC AGENTS | CELL THERAPEUTICS EUROPE S.R.L. (IT) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261980-A1 | Use of Thiazolidinone Derivatives as Antiangiogenic Agents | EP300, HIF1A, HIF1AN | ENPP2 2878/4885SYK 3137/4885MEN1 2216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.